enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
4.000
0.00 (0.00%)
At close: Apr 15, 2025, 4:00 PM
4.060
+0.060 (1.50%)
After-hours: Apr 15, 2025, 5:07 PM EDT
enGene Holdings Employees
As of October 31, 2024, enGene Holdings had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 24 or 72.73% compared to the previous year.
Employees
57
Change (1Y)
24
Growth (1Y)
72.73%
Revenue / Employee
n/a
Profits / Employee
-$1,211,351
Market Cap
203.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 57 | 24 | 72.73% |
| Oct 31, 2023 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCA Healthcare | 316,000 |
| Thermo Fisher Scientific | 125,000 |
| Medtronic | 95,000 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Novartis AG | 75,883 |
| Becton, Dickinson and Company | 73,000 |
| GSK plc | 68,629 |
ENGN News
- 11 days ago - enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 14 days ago - enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum - Business Wire
- 5 weeks ago - enGene Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - enGene to Participate in the Leerink Partners Global Healthcare Conference - Business Wire
- 6 weeks ago - enGene Holdings Inc.: Unknown Company Which Looks Like A Catch - Seeking Alpha
- 2 months ago - enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 2 months ago - enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) - Business Wire
- 4 months ago - enGene Reports Full Year 2024 Financial Results and Provides a Business Update - Business Wire